Research has shed light on how a new type of antibody treatment reactivates patients’ immune cells to fight ovarian cancer.

1. Compared to receiving intravenous (directly into a vein (IV)) anti-cancer therapy in hospital outpatient clinics, we are uncertain whether receiving the same therapy at home affects the management ...

AP402 targets p95HER2, a truncated form of HER2 present in 30-40% of HER2-positive cancers, which is associated with exceptionally poor prognosis, and not addressable by conventional anti-HER2 ...

GenAI offers a realistic path forward in tackling previously undruggable targets, with the potential to reshape the entire ...

Breakthrough research could make any IV drug able to be taken orally for a range of hard-to-treat cancers and other diseases, and redefine how medicines are designed, evaluated and delivered.

The new program at Hampton University’s Proton Cancer Institute works like a registry where patients undergoing treatment can ...

Alexander Kenigsberg, MD, discusses a new nonsurgical, robotic-focused ultrasound procedure for prostate cancer.

The Circleville Sunrise Rotary welcomed special guests from Touched by Cancer this week to highlight the importance of ...

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

A sweeping meta-analysis of over 10,000 studies has found that more than 70% support the use of medical cannabis in cancer ...

Anaplastic thyroid cancer (ATC), a rare yet highly aggressive malignancy, continues to represent a major clinical challenge.

A new wave of scientific interest is spotlighting GOT2—glutamic-oxaloacetic transaminase 2—as a compelling therapeutic target ...